Accordingly, curcumin derivative C817 has been shown to inhibit proliferation and down-regulate the BCR-ABL1 gene expression in imatinib-resistant CML cell models [54]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.